SAN DIEGO, June 11, 2018 /PRNewswire/ -- Halozyme
Therapeutics, Inc. (NASDAQ: HALO), a biotechnology company
developing novel oncology and drug-delivery therapies, today
announced Dr. Helen Torley,
president and chief executive officer, was awarded the honor of
Entrepreneur Of The Year® 2018 San Diego in the category
of Operational Excellence by a panel of independent judges.
The EY Entrepreneur Of The Year program recognizes the endeavors
of exceptional entrepreneurs who are excelling in areas such as
innovation, financial performance and personal commitment to their
businesses and communities. Now in its 32nd year, the program has
expanded to honor and recognize business leaders in more than 145
cities and more than 60 countries throughout the world.
"On behalf of the board of directors, I would like to
congratulate Helen and the entire Halozyme team for this
recognition of their work on behalf of patients, partners and
shareholders," said Connie L. Matsui, Halozyme chairman of the
board. "Under Helen's leadership, Halozyme has not only made
significant progress growing the ENHANZE technology franchise and
studying the potential for our investigational oncology drug, but
also in strengthening our culture and commitment to excellence. I
look forward to our continuing pursuit to make a difference in the
lives of patients."
In 2017, Halozyme generated three new ENHANZE®
technology agreements and expanded the number of anticipated
ENHANZE-partnered products in clinical studies to eight in 2018. In
January 2017, Halozyme announced the
positive topline results of its randomized phase 2 HALO-202 study
of PEGPH20 in combination with ABRAXANE®
(nab-paclitaxel) and gemcitabine chemotherapy in metastatic
pancreatic cancer patients. The company's ongoing Phase 3 clinical
trial, HALO-301, is anticipated to produce an interim analysis for
the first primary endpoint between December
2018 and February 2019.
"It is a true honor to accept this award on behalf of the
Halozyme team," said Dr. Torley. "Our progress reflects the
incredible passion and commitment each team member brings to
achieve our mission to improve the lives of patients through
advancing new therapies and easing the burden associated with
receiving important and often life-saving medicines."
As an EY Entrepreneur Of The Year San Diego award winner, Dr.
Torley is eligible for consideration for the Entrepreneur Of The
Year National competition. Award winners in several national
categories, as well as the Entrepreneur Of The Year National
Overall Award winner, will be announced at the Entrepreneur Of The
Year National Awards gala in Palm
Springs, California, on November
17.
About Entrepreneur Of The Year®
Entrepreneur Of The Year®, founded by EY, is the world's
most prestigious business awards program for entrepreneurs, chosen
from an independent panel of judges including entrepreneurs and
prominent leaders from business, finance, and the local community.
The program makes a difference through the way it encourages
entrepreneurial activity among those with potential and recognizes
the contribution of people who inspire others with their vision,
leadership and achievement. As the first and only truly global
awards program of its kind, Entrepreneur Of The Year celebrates
those who are building and leading successful, growing and dynamic
businesses, recognizing them through regional, national and global
awards programs in more than 145 cities in more than 60 countries.
ey.com/eoy
About Halozyme
Halozyme Therapeutics is a
biotechnology company focused on developing and commercializing
novel oncology therapies that target the tumor microenvironment.
Halozyme's lead proprietary program, investigational drug
pegvorhyaluronidase alfa (PEGPH20), applies a unique approach to
targeting solid tumors, allowing increased access of
co-administered cancer drug therapies to the tumor in animal
models. PEGPH20 is currently in development for metastatic
pancreatic cancer, non-small cell lung cancer, gastric cancer,
metastatic breast cancer and has potential across additional
cancers in combination with different types of cancer therapies. In
addition to its proprietary product portfolio, Halozyme has
established value-driving partnerships with leading pharmaceutical
companies including Roche, Baxalta, Pfizer, Janssen, AbbVie, Lilly,
Bristol-Myers Squibb and Alexion for its
ENHANZE® drug delivery technology. Halozyme is
headquartered in San Diego. For
more information visit www.halozyme.com.
Safe Harbor Statement In addition to historical
information, the statements set forth above include forward-looking
statements (including, without limitation, statements concerning
the Company's future expectations and plans for growth in 2018,
entering into new collaboration agreements, the development and
commercialization of product candidates, including timing of
clinical trial results announcements and future development and
commercial activities of our collaboration partners, the potential
benefits and attributes of such product candidates and expected
financial outlook for 2018) that involve risk and uncertainties
that could cause actual results to differ materially from those in
the forward-looking statements. The forward-looking statements are
typically, but not always, identified through use of the words
"believe," "enable," "may," "will," "could," "intends," "estimate,"
"anticipate," "plan," "predict," "probable," "potential,"
"possible," "should," "continue," and other words of similar
meaning. Actual results could differ materially from the
expectations contained in forward-looking statements as a result of
several factors, including unexpected expenditures and costs,
unexpected fluctuations or changes in revenues, including revenues
from collaborators, unexpected delays in entering into new
collaboration agreements, unexpected results or delays in
development of product candidates, including delays in clinical
trial patient enrollment and development activities of our
collaboration partners, and regulatory review, regulatory approval
requirements, unexpected adverse events and competitive conditions.
These and other factors that may result in differences are
discussed in greater detail in the Company's Quarterly Report on
Form 10-Q filed with the Securities and Exchange Commission on
May 10, 2018.
Contacts:
Jim
Mazzola
858-704-8122
ir@halozyme.com
Chris Burton
858-704-8352
ir@halozyme.com
View original content with
multimedia:http://www.prnewswire.com/news-releases/halozyme-president-and-chief-executive-officer-dr-helen-torley-named-ey-entrepreneur-of-the-year-2018-san-diego-300663838.html
SOURCE Halozyme Therapeutics, Inc.